A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (GOG 3015)
James Hoffman, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199
The purpose of this study is to research the effects, good or bad, of atezolizumab on your specific type of cancer (ovarian, fallopian tube, or primary peritoneal). Atezolizumab is an experimental drug. However, atezolizumab is approved in the United States (U.S.) for the treatment of locally advanced or metastatic bladder cancer (urothelial carcinoma) and non-small cell lung cancer that came back after getting platinum-containing chemotherapy.
Newly-diagnosed stage III/IV ovarian, fallopian tube, or primary peritoneal cancer